Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294833 | 0.90 | KCNN4 (0.40) | KIF11MPOMEN1MAPTKMT2A | |
| SCHEMBL16346695 | 0.87 | SCN5A (0.42) | KIF11SLC22A12CYP19A1PPARGSCN5A | |
| SCHEMBL13199336 | 0.86 | PGK1 (0.48) | MEN1MAPTKMT2ACYP1A2ALDH1A1 | |
| SCHEMBL20591894 | 0.85 | MEN1 (0.41) | KIF11MPOMEN1MAPTKMT2A | |
| SCHEMBL3888184 | 0.83 | SCN5A (0.49) | KIF11MEN1MAPTKMT2ACYP1A2 | |
| SCHEMBL25007317 | 0.82 | CES1 (0.48) | KIF11PARP1LMNANPC1RAB9A | |
| SCHEMBL31560780 | 0.81 | PKM (0.44) | KIF11MPOMEN1MAPTKMT2A | |
| SCHEMBL28603099 | 0.81 | PKM (0.44) | KIF11MPOMEN1MAPTKMT2A | |
| Bromomethane SCHEMBL4026722 | 0.80 | KIF11 (0.41) | KIF11MPOMEN1MAPTKMT2A | |
| SCHEMBL30032454 | 0.80 | PTPN1 (0.50) | KIF11MPOMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10483466-B2 | P-doping cross-linking of organic hole transporters | SIEMENS AKTIENGESELLSCHAFT (DE) | 2019-11-19 | — | — | US | claimed |
| EP-3114715-B1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | SIEMENS AG (DE) | 2019-10-30 | — | — | EP | claimed |
| US-20180198069-A1 | P-Doping Cross-Linking Of Organic Hole Transporters | SIEMENS AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | claimed |
| EP-3114715-A1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | Siemens Aktiengesellschaft (DE) | 2017-01-11 | — | — | EP | claimed |
| US-20250185502-A1 | ORGANIC OPTOELECTRONIC COMPONENT, ORGANIC FUNCTIONAL LAYER, AND METHOD FOR PRODUCING AN OPTOELECTRONIC COMPONENT | OSRAM OLED GMBH (DE) | 2025-06-05 | — | — | US | disclosed |
| US-12302747-B2 | Optoelectronic component, organic functional layer, and method for producing an optoelectronic component | OSRAM OLED GMBH (DE) | 2025-05-13 | — | — | US | disclosed |
| EP-4193399-B1 | ELECTRONIC DEVICE | MERCK PATENT GMBH (DE) | 2025-01-29 | — | — | EP | disclosed |
| EP-3210248-B2 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2024-04-10 | — | — | EP | disclosed |
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20150162534-A1 | METAL COMPLEXES AS P-TYPE DOPANTS FOR ORGANIC ELECTRONIC MATRIX MATERIALS | OSRAM OLED GMBH (DE) | 2015-06-11 | — | — | US | disclosed |
| CN-104685647-A | Main group metal complexes as p-dopants for organic electronic matrix materials | SIEMENS AG | 2015-06-03 | — | — | CN | disclosed |
| US-20150123047-A1 | MAIN GROUP METAL COMPLEXES AS P-DOPANTS FOR ORGANIC ELECTRONIC MATRIX MATERIALS | OSRAM OLED GMBH (DE) | 2015-05-07 | — | — | US | disclosed |
| CN-104541383-A | Metal complexes as p-type dopants for organic electronic matrix materials | SIEMENS AG | 2015-04-22 | — | — | CN | disclosed |
| CN-102399227-A | Synthesis process of anti-tumor novel medicine 3- { (3-chlorphenyl) difluoromethyl-1-isopropyl-1H-pyrazolo (3,4-D) pyrimidine-4-amine compound | SHENGSHI TAIKE BIOMEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-04-04 | — | — | CN | disclosed |
| US-5300527-A | Administering anticholinergic agents for treating the memory dysfunction | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-04-05 | — | — | US | disclosed |
| US-5177111-A | Analgesic | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-01-05 | — | — | US | disclosed |
| US-5006563-A | Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | KIF11 4276/4885MPO 4078/4885MEN1 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.